HK1257882A1 - 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 - Google Patents

通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 Download PDF

Info

Publication number
HK1257882A1
HK1257882A1 HK19100243.4A HK19100243A HK1257882A1 HK 1257882 A1 HK1257882 A1 HK 1257882A1 HK 19100243 A HK19100243 A HK 19100243A HK 1257882 A1 HK1257882 A1 HK 1257882A1
Authority
HK
Hong Kong
Prior art keywords
methods
multiple myeloma
treating multiple
cell leukemia
plasma cell
Prior art date
Application number
HK19100243.4A
Other languages
English (en)
Chinese (zh)
Inventor
科伊内 冈瑟
科伊內 岡瑟
Original Assignee
纪念斯隆-凯特林癌症中心
紀念斯隆-凱特林癌症中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 纪念斯隆-凯特林癌症中心, 紀念斯隆-凱特林癌症中心 filed Critical 纪念斯隆-凯特林癌症中心
Publication of HK1257882A1 publication Critical patent/HK1257882A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK19100243.4A 2015-09-10 2016-09-09 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法 HK1257882A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
HK1257882A1 true HK1257882A1 (zh) 2019-11-01

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100243.4A HK1257882A1 (zh) 2015-09-10 2016-09-09 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法

Country Status (14)

Country Link
US (1) US20190381098A1 (https=)
EP (1) EP3347028A1 (https=)
JP (1) JP6947720B2 (https=)
KR (1) KR20180048992A (https=)
CN (1) CN108348552A (https=)
AU (1) AU2016320877A1 (https=)
CA (1) CA2997757A1 (https=)
HK (1) HK1257882A1 (https=)
IL (1) IL257929B2 (https=)
MX (1) MX395106B (https=)
RU (1) RU2743381C2 (https=)
TW (1) TWI759270B (https=)
WO (1) WO2017044678A1 (https=)
ZA (1) ZA201801656B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
CN108348552A (zh) 2018-07-31
TWI759270B (zh) 2022-04-01
IL257929B1 (en) 2024-02-01
WO2017044678A1 (en) 2017-03-16
IL257929B2 (en) 2024-06-01
EP3347028A1 (en) 2018-07-18
US20190381098A1 (en) 2019-12-19
ZA201801656B (en) 2022-12-21
TW201714619A (zh) 2017-05-01
RU2018112526A (ru) 2019-10-10
KR20180048992A (ko) 2018-05-10
JP2018530534A (ja) 2018-10-18
RU2743381C2 (ru) 2021-02-17
MX395106B (es) 2025-03-21
IL257929A (en) 2018-05-31
JP6947720B2 (ja) 2021-10-13
CA2997757A1 (en) 2017-03-16
AU2016320877A1 (en) 2018-04-19
MX2018002816A (es) 2018-06-08
RU2018112526A3 (https=) 2020-01-31

Similar Documents

Publication Publication Date Title
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
HK1257187B (zh) 包含非天然胰腺β细胞的装置以及在治疗疾病如糖尿病中的用途
CA2956871C (en) Compounds active towards bromodomains
PH12017500803A1 (en) Anti-pd-1 antibodies
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
NZ742327A (en) Neural cell extracellular vessicles
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
EP4591935A3 (en) Methods for the preparation of ribosides
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2018005521A3 (en) Cell culture chambers and methods of use thereof
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2015015231A (es) Métodos y composiciones para mejorar las células t reguladoras de cd4+.
MX356210B (es) Formulaciones de polimero acrilico.
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
WO2012158437A3 (en) Cannula apparatus and ventricular assist systems using the cannula apparatus
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2019000677A (es) Células miméticas de células b.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12017501979A1 (en) Pharmaceutical compound
IL276979A (en) Macro-encapsulation of medicinal cells, devices and methods in their use